Name:
Conatumumab Biosimilar, Anti-CD262/TNFRSF10B/TRAIL-R2
Host species:
Homo sapiens
Species reactivity:
Human
Form:
solution
Storage buffer:
0.01M PBS, pH 7.4.
Concentration:
1 mg/ml
Purity:
>95%.category：Monoclonal
Isotype:
IgG1-kappa
Applications:
Biosimilar
For research use only. We do not sell to patients.
Target:
TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2
Purification:
Protein A/G purified from cell culture supernatant.
Endotoxin level:
Please contact with the lab for this information.
Expression system:
MammalianO14763https://www.ncbi.nlm.nih.gov/protein/O14763
Stability and Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4C short term
1-2 weeks:
.Store at -20 C 12 months. Store at -80C long term.
Alternative Names:
AMG 655, TRAIL-R2mAb, XG1-048 v w, CAS: 896731-82-1Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Adiponectin receptor protein 1 Antibody
FEN1 Antibody (YA765)
SIRT3 Antibody: SIRT3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 44 kDa, targeting to SIRT3. It can be used for WB,IHC-P assays with tag free, in the background of Human.
